INM INMED PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended March 31, 2026, INMED PHARMACEUTICALS INC reported revenue of n/a, net income of −$2.97M and diluted EPS of −$0.73; for the fiscal year ended June 2025 revenue was $4.94M, up 7.5% on the year before.

INM annual revenue and earnings

• Fiscal year ended Jun 2025: revenue $4.94M, gross profit $1.71M, operating income n/a, net income −$8.16M (margin -165.1%), EPS −$8.36
• Fiscal year ended Jun 2024: revenue $4.60M, gross profit $1.10M, operating income n/a, net income −$7.68M (margin -166.9%), EPS −$20.14
• Fiscal year ended Jun 2023: revenue $4.14M, gross profit $1.40M, operating income −$7.95M, net income −$7.95M (margin -192.2%), EPS −$3.25
• Fiscal year ended Jun 2022: revenue $1.09M, gross profit $544K, operating income −$18.6M, net income −$18.6M (margin -1707.3%), EPS −$33.17
• Fiscal year ended Jun 2021: revenue $1.90M, gross profit n/a, operating income −$10.2M, net income −$10.2M (margin -535.9%), EPS −$37.96

INM quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue n/a, net income −$2.97M, EPS −$0.73
• Quarter ended Dec 31, 2025: revenue $820K (down 26.2% year over year), net income −$2.03M, EPS −$0.51
• Quarter ended Sep 30, 2025: revenue $1.12M (down 11.4% year over year), net income −$1.73M, EPS −$0.44
• Quarter ended Jun 30, 2025 (from the annual report): revenue $1.30M (up 1.7% year over year), net income −$1.79M, EPS −$0.07
• Quarter ended Mar 31, 2025: revenue $1.26M (up 7.6% year over year), net income −$2.12M, EPS −$1.94
• Quarter ended Dec 31, 2024: revenue $1.11M (down 10.4% year over year), net income −$2.58M, EPS −$3.64
• Quarter ended Sep 30, 2024: revenue $1.26M (up 40.2% year over year), net income −$1.68M, EPS −$2.71
• Quarter ended Jun 30, 2024 (from the annual report): revenue $1.28M (down 44.5% year over year), net income −$1.94M, EPS $2.39
• Quarter ended Mar 31, 2024: revenue $1.17M (up 13.4% year over year), net income −$1.72M, EPS −$3.58
• Quarter ended Dec 31, 2023: revenue $1.24M (up 164.0% year over year), net income −$1.48M, EPS −$3.71
• Quarter ended Sep 30, 2023: revenue $902K (up 181.1% year over year), net income −$2.54M, EPS −$15.24
• Quarter ended Jun 30, 2023 (from the annual report): revenue $2.31M, net income −$338K, EPS $2.32
• Quarter ended Mar 31, 2023: revenue $1.03M (up 234.0% year over year), net income −$2.00M, EPS −$0.60
• Quarter ended Dec 31, 2022: revenue $470K (up 77.2% year over year), net income −$2.10M, EPS −$0.91
• Quarter ended Sep 30, 2022: revenue $321K, net income −$3.51M, EPS −$4.06
• Quarter ended Jun 30, 2022 (from the annual report): revenue n/a, net income −$7.87M, EPS −$13.13
• Quarter ended Mar 31, 2022: revenue $310K (down 29.2% year over year), net income −$3.48M, EPS −$6.14
• Quarter ended Dec 31, 2021: revenue $265K, net income −$4.28M, EPS −$7.73
• Quarter ended Sep 30, 2021: revenue n/a, net income −$2.97M, EPS −$6.17
• Quarter ended Mar 31, 2021: revenue $437K, net income −$3.10M, EPS −$0.41

INM cash flow, buybacks and dividends

• Fiscal year ended Jun 2025: operating cash flow −$8.10M, share buybacks n/a
• Fiscal year ended Jun 2024: operating cash flow −$6.99M, share buybacks n/a
• Fiscal year ended Jun 2023: operating cash flow −$7.28M, share buybacks n/a
• Fiscal year ended Jun 2022: operating cash flow −$15.6M, share buybacks n/a
• Fiscal year ended Jun 2021: operating cash flow −$9.79M, share buybacks n/a

INM balance sheet

• Jun 30, 2026: cash n/a, total assets $3.03M, total liabilities $1.96M, shareholders' equity $1.08M
• Mar 31, 2026: cash $5.16M, total assets $9.13M, total liabilities $2.24M, shareholders' equity $6.89M
• Dec 31, 2025: cash $6.95M, total assets $11.2M, total liabilities $1.60M, shareholders' equity $9.59M
• Sep 30, 2025: cash $9.33M, total assets $13.4M, total liabilities $1.77M, shareholders' equity $11.6M
• Jun 30, 2025: cash $10.7M, total assets $15.6M, total liabilities $2.15M, shareholders' equity $13.4M
• Mar 31, 2025: cash $4.68M, total assets $9.28M, total liabilities $2.26M, shareholders' equity $7.02M
• Dec 31, 2024: cash $3.42M, total assets $8.50M, total liabilities $2.32M, shareholders' equity $6.18M
• Sep 30, 2024: cash $5.58M, total assets $10.5M, total liabilities $2.07M, shareholders' equity $8.40M

What is INM's revenue?

INMED PHARMACEUTICALS INC reported $4.94M of revenue for the fiscal year ended June 2025.

Is INM profitable?

No. INMED PHARMACEUTICALS INC lost $8.51M over the last four quarters.

What is INM's EPS?

Diluted earnings per share over the last four quarters were −$1.75; −$0.73 in the latest quarter.

INM ownership and insider trades · All stocks